Uniunea Europeană -
estoniană -
EMA (European Medicines Agency)
gamifant
swedish orphan biovitrum ab (publ) - emapalumab - immune system diseases - gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (hlh).
Uniunea Europeană -
estoniană -
EMA (European Medicines Agency)
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulaarne blokaad - kõik muud ravitoimingud - rookurooniumi või vekurooniumi poolt indutseeritud neuromuskulaarse blokaadi pöördumine. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Estonia -
estoniană -
Ravimiamet
tresuvi infusioonilahus
orpha-devel handels und vertriebs gmbh - treprostiniil - infusioonilahus - 2,5mg 1ml 10ml 1tk
Estonia -
estoniană -
Ravimiamet
tresuvi infusioonilahus
orpha-devel handels und vertriebs gmbh - treprostiniil - infusioonilahus - 10mg 1ml 10ml 1tk
Estonia -
estoniană -
Ravimiamet
tresuvi infusioonilahus
orpha-devel handels und vertriebs gmbh - treprostiniil - infusioonilahus - 5mg 1ml 10ml 1tk
Estonia -
estoniană -
Ravimiamet
tresuvi infusioonilahus
orpha-devel handels und vertriebs gmbh - treprostiniil - infusioonilahus - 1mg 1ml 10ml 1tk
Estonia -
estoniană -
Ravimiamet
nexodal 0,4 mg/ml süste-/infusioonilahus
orpha-devel handels und vertriebs gmbh - naloksoon - süste-/infusioonilahus - 0,4mg 1ml 1ml 10tk
Estonia -
estoniană -
Ravimiamet
nalpain süstelahus
orpha-devel handels und vertriebs gmbh - nalbufiin - süstelahus - 10mg 1ml 2ml 10tk
Estonia -
estoniană -
Ravimiamet
multiferon süstelahus
swedish orphan biovitrum international ab - alfainterferoon - süstelahus - 3000000rÜ 0.5ml 0.5ml 6tk
Uniunea Europeană -
estoniană -
EMA (European Medicines Agency)
aspaveli
swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinuuria, paroksüsmaalne - immunosupressandid - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.